Persistent UnprofitabilitySustained negative EBIT and net losses weaken the firm's ability to generate returns and reinvest internally. Extended unprofitability risks continual equity dilution or external funding needs, constraining strategic initiatives and reducing resilience to setbacks during multi‑year commercialization efforts.
Weak Cash GenerationZero operating and free cash flow indicate the business currently does not self‑fund operations or growth. This structural cash shortfall raises execution risk for clinical trials, sales expansion, and inventory buildup, increasing reliance on external financing and pressuring long‑term sustainability.
Negative Return On EquityA negative ROE shows capital is not producing shareholder returns, signaling inefficient use of equity. Over time this undermines investor confidence, may force capital raises or strategy shifts, and limits the company's ability to build long‑term shareholder value without a clear path to profitability.